Loading stock data…
SLNO
$52.87+0.05 (+0.09%)
Market ClosedLast close May 1
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Soleno Therapeutics, Inc. in the Healthcare sector is trading at $52.87. The stock is currently 41% below its 52-week high of $90.32, remaining 2.5% below its 200-day moving average. Technical signals show neutral RSI of 64 and bearish MACD signal, explaining why SLNO maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 64) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$52.87
Potential Downside
92.6%
Whystock Fair Value$3.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Hold
Mean target$53.00+0.2%
Range$53.00 – $53.00
Fundamentals
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
135.26
Beta
Defensive asset. Lower volatility than the S&P 500.
-2.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.23%
Volume
Today's trading volume
1.21M
Recent News
Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal
After surging 57.56% so far in April, Soleno Therapeutics, Inc. (NASDAQ:SLNO) secures a spot on our list of the mid-cap stocks with the highest gains in April. On April 6, 2026, Neurocrine, an American biopharmaceutical company, announced the acquisition of Soleno Therapeutics, Inc. (NASDAQ:SLNO). After the announcement, Soleno shares surged nearly 33% in early trading. […]
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story
Neurocrine Biosciences (NasdaqGS:NBIX) has entered a definitive agreement to acquire Soleno Therapeutics. The deal adds Vykat XR, the first FDA approved therapy for hyperphagia in Prader Willi syndrome, to Neurocrine's portfolio. The transaction extends Neurocrine's presence in rare diseases and endocrinology with a therapy that has long intellectual property protection. For investors watching Neurocrine Biosciences at a current share price of $132.48, this move expands the product lineup...
Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls
Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls
Company News for Apr 7, 2026
Companies in The News Are: SLNO,NBIX,MU,AAPL,SNDK